Renal cell carcinoma (RCC) is a challenging cancer to uncover early in the course of disease, as more than half of patients report no symptoms. For patients with localized disease, the prognosis is excellent, with a 5-year survival of nearly 93%. The other end of the spectrum—advanced metastatic disease—portends a mere 13% 5-year survival, but improvements in treatment are poised to improve those odds. In this case-based interactive forum, three experts in genitourinary malignancies share the art and science of applying targeted and immunotherapies to the treatment of patients with advanced RCC to improve outcomes and quality of life.
Interactive video lecture
After completing this activity, participants should be better able to:
- Assess available combination therapy based on the most recent clinical trial data
- Integrate targeted and immunotherapies into the treatment of patients with advanced RCC as appropriate
- Apply recommended monitoring and management strategies for immune-related adverse events in patients treated with immunotherapies and tyrosine kinase inhibitors for RCC
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until March 19, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA Course Advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was developed from a live program cosupported by educational grants from AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck & Co., Inc.; and Taiho Oncology, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Exelixis.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Gao: advisory board: Exelixis.
Dr Liu: speakers bureau: Astellas, Eisai, EMD Serono, Exelixis.
Ms Sims has no relevant financial relationships to disclose.
Ms Williams: speakers bureau: AstraZeneca.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: March 20, 2021
Expiration date: March 19, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 100320BTC-7B